Cryofocus Medtech (Shanghai) Co., Ltd. (HKG:6922)
Hong Kong
· Delayed Price · Currency is HKD
4.090
+0.020 (0.49%)
At close: Apr 22, 2025, 4:00 PM HKT
HKG:6922 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 53.53 | 40.95 | 27.15 | 22.43 | 9.05 |
| Revenue Growth (YoY) | 30.72% | 50.83% | 21.06% | 147.69% | - |
| Cost of Revenue | 15.12 | 9.9 | 7.79 | 6.88 | 4.41 |
| Gross Profit | 38.41 | 31.05 | 19.36 | 15.55 | 4.64 |
| Selling, General & Admin | 95.28 | 74.7 | 88.33 | 55.56 | 126.9 |
| Research & Development | 73.46 | 76.13 | 59.93 | 38.85 | 42.31 |
| Operating Expenses | 168.74 | 150.82 | 148.26 | 94.41 | 169.21 |
| Operating Income | -130.33 | -119.77 | -128.9 | -78.87 | -164.57 |
| Interest Expense | -1.09 | -0.65 | -0.59 | -0.38 | -0.04 |
| Interest & Investment Income | 0.23 | 1.22 | 1.19 | 2.98 | 1.29 |
| Currency Exchange Gain (Loss) | 1.16 | 1.7 | 2.62 | - | -0.01 |
| Other Non Operating Income (Expenses) | 18.89 | 11.75 | 7.36 | 0.74 | 3.69 |
| EBT Excluding Unusual Items | -111.14 | -105.75 | -118.32 | -75.52 | -159.64 |
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.31 |
| Other Unusual Items | - | - | - | -50.97 | - |
| Pretax Income | -111.14 | -105.75 | -118.32 | -126.5 | -159.33 |
| Income Tax Expense | 0.13 | - | - | - | - |
| Earnings From Continuing Operations | -111.28 | -105.75 | -118.32 | -126.5 | -159.33 |
| Minority Interest in Earnings | 6.91 | 8.26 | 6.09 | 24.62 | 22.25 |
| Net Income | -104.37 | -97.49 | -112.22 | -101.87 | -137.09 |
| Net Income to Common | -104.37 | -97.49 | -112.22 | -101.87 | -137.09 |
| Shares Outstanding (Basic) | 239 | 239 | 228 | 228 | - |
| Shares Outstanding (Diluted) | 239 | 239 | 228 | 228 | - |
| Shares Change (YoY) | - | 4.86% | 0.01% | - | - |
| EPS (Basic) | -0.44 | -0.41 | -0.49 | -0.45 | - |
| EPS (Diluted) | -0.44 | -0.41 | -0.49 | -0.45 | - |
| Free Cash Flow | - | -111 | -103.95 | -74.93 | -35.71 |
| Free Cash Flow Per Share | - | -0.46 | -0.46 | -0.33 | - |
| Gross Margin | 71.75% | 75.83% | 71.32% | 69.32% | 51.25% |
| Operating Margin | -243.46% | -292.48% | -474.77% | -351.68% | -1817.59% |
| Profit Margin | -194.96% | -238.06% | -413.36% | -454.26% | -1514.08% |
| Free Cash Flow Margin | - | -271.05% | -382.87% | -334.11% | -394.45% |
| EBITDA | -124.91 | -114.35 | -124.34 | -76.14 | -162.28 |
| EBITDA Margin | -233.33% | -279.25% | - | - | - |
| D&A For EBITDA | 5.42 | 5.42 | 4.55 | 2.73 | 2.28 |
| EBIT | -130.33 | -119.77 | -128.9 | -78.87 | -164.57 |
| EBIT Margin | -243.46% | -292.48% | - | - | - |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.